Immunodermatology News

The annual American Society for Dermatologic Surgery meeting was recently held in Chicago, bringing together a wide variety of clinical knowledge, techniques and news.

Almirall announced its 9-month 2023 financial results, which included a year-on-year net sales increase of 6.4% due to its European sales, according to a company press release.

Treatment with Janus kinase inhibitors may be associated with elevated odds of acne, especially among those with dermatologic conditions, according to a study.

Mounting evidence suggests that herpes simplex virus 1 may be associated with an increased risk for Alzheimer’s disease and dementia, according to a systematic review of published studies.

The Skindex-16, a clinical tool for measuring the skin-related quality of life of patients, showed that patients with autoimmune bullous diseases are greatly impacted by disease flares, according to a study.

Two widely available serum marker blood tests, galactomannan and 1,2-beta-D-glucan, may improve diagnostic sensitivity in cases of invasive fungal infections, according to a study.

Samsung Bioepis Co. Ltd. announced in a press release that the company has entered a commercialization agreement with Sandoz for SB17, a proposed biosimilar to Stelara.

Patients that experience cutaneous immune-related adverse events after immune checkpoint inhibitor treatment are more likely to survive their melanoma diagnosis, according to a study.

While the adoption of immunotherapies and targeted systemic therapies for the treatment of melanoma has increased overall survival in patients, it has also significantly increased health care costs, according to a study.

Based on the pathogenesis of eosinophilic cellulitis, treatment targeting Janus kinase 1 and 2 should be developed to treat this disease, according to a study.